Search
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideVilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnOn May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. … Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury.
Vorasidenib
go.drugbank.com/drugs/DB17097ApprovedInvestigationalVorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. … [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms.
Ferric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalThe latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020. … Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide.
Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoulesHydroxyproline
go.drugbank.com/drugs/DB08847ApprovedTherapeutically, hydroxyproline is being studied as an an experimental medicine but is approved in France as a combination topical gel product called Cicactive for small, superficial wounds. … It is found in collagen and as such it is common in many gelatin products. Hydroxyproline is mostly used as a diagnostic marker of bone turnover and liver fibrosis.
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Synonyms: N-formimidoylthienamycin, N-formimidoyl thienamycinMixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNPralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … [A246693] Compared to methotrexate, pralatrexate has better accumulation in cancer cells.
Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acidLevomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. … [A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].
Synonyms: CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1S,2R)-